title: Role of urokinase-type plasminogen activator in local immunotherapy.
abstract: We have previously reported that intratumoral injection of a mixture of OK-432 and fibrinogen (OK/fbg) is very effective for local immunotherapy of colorectal cancer, but has little influence on breast cancer, while addition of activated macrophages to OK/fbg (OK/fbg/mo) has a marked effect on breast cancer. In this study, we analyzed the role of urokinase-type plasminogen activator (uPA) in local immunotherapy. We found that uPA levels in breast cancer tissue were lower than in colorectal cancer tissue. Injection of OK-432 into breast cancers neither increased the uPA level nor caused tumor regression. Although OK/fbg injection caused an increase of uPA, tumor regression was restricted to the area around the injection site. With OK/fbg/mo however, uPA levels increased much more markedly and extensive tumor necrosis was observed in all cases. These findings suggest that uPA plays an important role in tumor regression during local immunotherapy.
authors.affiliation: Department of Surgery II, Osaka University, Medical School 2-2, Yamada-oka, Suita, Osaka, 565, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Takeda
authors.forename: Y
authors.initials: Y
authors.lastname: Ito
authors.forename: E
authors.initials: E
authors.lastname: Wakasugi
authors.forename: T
authors.initials: T
authors.lastname: Kobayashi
authors.forename: M
authors.initials: M
authors.lastname: Monden
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000201:enzymology* / Q000473:pathology / Q000628:therapy; D015179:Colorectal Neoplasms / Q000201:enzymology / Q000473:pathology / Q000628:therapy; D003602:Cytotoxicity, Immunologic; D004359:Drug Therapy, Combination; D005260:Female; D005340:Fibrinogen / Q000008:administration & dosage*; D006801:Humans; D007167:Immunotherapy; D015552:Injections, Intralesional; D008264:Macrophages / Q000378:metabolism; D009336:Necrosis; D009367:Neoplasm Staging; D010844:Picibanil / Q000008:administration & dosage / Q000627:therapeutic use*; D017154:Stromal Cells / Q000378:metabolism; D014568:Urokinase-Type Plasminogen Activator / Q000502:physiology*
chemical_list: D000970:Antineoplastic Agents; D010844:Picibanil; D005340:Fibrinogen; D014568:Urokinase-Type Plasminogen Activator